EMA challenged over "revolving door" involving former head
This article was originally published in SRA
Executive Summary
The European Medicines Agency's decision to allow its former executive director, Thomas Lönngren, to join private sector companies just weeks after leaving his post at the agency has been criticised by public health and transparency campaigners, who are concerned "that rules regarding conflicts of interest may not have been respected" in this case1.